lapatinib hepatoxicity investigated (article by the drug co. that makes it)
 

Drug Metab Dispos. 2011 Sep 30. [Epub ahead of print]
Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity.
Castellino S, O'Mara MJ, Koch KM, Borts D, Bowers GD, Maclauchlin C.
Source
1 GlaxoSmithKline;
Abstract
Lapatinib (Tykerb/Tyverb) is an important orally active dual tyrosine kinase inhibitor efficacious in combination therapy for patients with progressive HER2-overexpressing metastatic breast cancer. However, clinically significant liver injury has been reported which may be associated with lapatinib metabolic activation. We describe the metabolism and excretion of [(14)C]-lapatinib in six healthy human volunteers following a single oral dose of 250 mg and the potential relationships between metabolism and clinical hepatotoxicity. Overall, elimination showed high inter-subject variability, with fecal elimination being the predominant pathway representing a median of 92% of the dose with lapatinib as the largest component (ca. median 27% dose). In plasma, approximately 50% of the observed radioactivity was attributed to metabolites. Analysis of a 4 hour pooled plasma extract identified seven metabolites related by an N- and αcarbon oxidation cascade and oxidation. Fecal metabolites derived from three prominent pathways: N- and αcarbon oxidation, fluorobenzyl oxidative cleavage, and hydroxypyridine formation. Undoubtedly, several of the lapatinib metabolites can be linked to reactive species such as aldehydes or quinone imines. In addition to the contribution of these potentially reactive metabolites as suspects in clinical liver injury, the role of other disposition factors, including interaction with drug transporters, pharmacogenetics, or magnitude of the therapeutic dose, should not be discounted.

PMID: 21965624

Re: lapatinib hepatoxicity investigated (article by the drug co. that makes it)
 

Lani, thanks for posting this. Very interesting. How do you come across articles like this? I am impressed at the information that comes across this board---so helpful.

Re: lapatinib hepatoxicity investigated (article by the drug co. that makes it)
 

Umm...so...unclear what symptoms or lab values would be associated with the toxicity.

Re: lapatinib hepatoxicity investigated (article by the drug co. that makes it)
 

signs of liver injury are usually elevated liver enzymes

Perhaps at late stages serum albumin might be decreased if the liver is not able to make enough

Signs of liver toxicity might be due to lack of serum albumin or too much ammonia in the blood (poor cognition)

As to how I come across this sort of information, I peruse PubMed 5 days weekly (Tuesday-Saturday) when new articles get added

Re: lapatinib hepatoxicity investigated (article by the drug co. that makes it)
 

Thanks Lani.I was wondering why every time before an appointment the Onc was ordering a liver function test in addition to CBC.

Re: lapatinib hepatoxicity investigated (article by the drug co. that makes it)
 

pibikay,
I think liver function tests are pretty important when liver mets are present, regardless of the treatment.

Lani,
Do you have access to the full article? I was just wondering how toxicity was defined in the paper.

Anecdotally, seems like most patients have no issue with Tykerb and liver function. But when it happens, seems to be pretty pronounced and the drug is stopped.

Re: lapatinib hepatoxicity investigated (article by the drug co. that makes it)
 

if you go to entrez pubmed via google and enter the PMID number at the end of the abstract it turns out the entire article is free access